Mechanisms of p53 degradation

被引:106
|
作者
Chao, Chuck C. -K. [1 ,2 ]
机构
[1] Chang Gung Univ, Coll Med, Dept Biochem & Mol Biol, Taoyuan 333, Taiwan
[2] Chang Gung Univ, Coll Med, Grad Inst Biomed Sci, Taoyuan 333, Taiwan
关键词
De-ubiquitinating enzyme; E3; ligase; Mdm2; p53; Proteasome; Ubiquitin; UBIQUITIN-PROTEIN LIGASE; PROTEASOME-MEDIATED DEGRADATION; NERVOUS-SYSTEM DEVELOPMENT; SENSITIZES CANCER-CELLS; TUMOR-SUPPRESSOR P53; IN-VIVO; REGULATE P53; TRANSCRIPTIONAL ACTIVITY; DEUBIQUITINATING ENZYME; CDT1; PROTEOLYSIS;
D O I
10.1016/j.cca.2014.08.015
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The tumor suppressor p53 plays various functional roles in the cell by regulating multiple regulatory signals that ensure adequate temporal and spatial responses to cellular stress. p53 is usually kept inactive due to ubiquitination by a number of E3 ubiquitin ligases that target p53 for proteasomal degradation. The ubiquitously expressed proto-oncogene Mdm2 is the major E3 ubiquitin ligase involved in this process and is critical for regulating p53 homeostasis. Ubiquitination by E3 ligases may induce cellular relocation of p53 and determine the outcome of p53-mediated stress response, including cell proliferation, apoptosis and efficacy of cancer therapy. In addition to marking p53 for proteasomal degradation, ubiquitination acts as a signal for the degradation-independent functions of p53, such as nuclear export and transcriptional activation. Importantly, the reversible nature of the ubiquitination process and the identification of de-ubiquitination enzymes acting on p53 have added yet another layer of regulatory mechanism controlling p53 activity. This review highlights our current understanding of the mechanisms underlying p53 degradation as well as the significance of the p53 pathway in response to genotoxic stress. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:139 / 147
页数:9
相关论文
共 50 条
  • [1] New insights into regulation of p53 protein degradation
    Guo, Tao
    Gu, Chundong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (06): : 8773 - 8779
  • [2] Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
    DeVine, Tiffany
    Dai, Mu-Shui
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (18) : 3248 - 3262
  • [3] Protecting p53 from degradation
    Lain, S
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 482 - 485
  • [4] On the involvement of calpains in the degradation of the tumor suppressor protein p53
    Gonen, H
    Shkedy, D
    Barnoy, S
    Kosower, NS
    Ciechanover, A
    FEBS LETTERS, 1997, 406 (1-2) : 17 - 22
  • [5] Updates on p53: modulation of p53 degradation as a therapeutic approach
    Dey, A.
    Verma, C. S.
    Lane, D. P.
    BRITISH JOURNAL OF CANCER, 2008, 98 (01) : 4 - 8
  • [6] Updates on p53: modulation of p53 degradation as a therapeutic approach
    A Dey
    C S Verma
    D P Lane
    British Journal of Cancer, 2008, 98 : 4 - 8
  • [7] Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation
    Hjerpe, Roland
    Aillet, Fabienne
    Lopitz-Otsoa, Fernando
    Lang, Valerie
    Torres-Ramos, Monica
    Farras, Rosa
    Hay, Ronald T.
    Rodriguez, Manuel S.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2010, 42 (05) : 725 - 735
  • [8] Tickets for p53 journey among organelles
    Ferecatu, Ioana
    Rincheval, Vincent
    Mignotte, Bernard
    Vayssiere, Jean-Luc
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 : 4214 - 4228
  • [9] Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex
    Carra, Giovanna
    Crivellaro, Sabrina
    Taulli, Riccardo
    Guerrasio, Angelo
    Saglio, Giuseppe
    Morotti, Alessandro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (12)
  • [10] Mechanisms of transcriptional regulation by p53
    Sullivan, Kelly D.
    Galbraith, Matthew D.
    Andrysik, Zdenek
    Espinosa, Joaquin M.
    CELL DEATH AND DIFFERENTIATION, 2018, 25 (01) : 133 - 143